Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  1/5/2016
Miami Jewish Health System
mi
from
Miami, FL
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 1/5/2016
Miami Jewish Health System
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  1/5/2016
St. Louis Clinical Trials
mi
from
St. Louis, MO
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 1/5/2016
St. Louis Clinical Trials
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  1/5/2016
CRI Lifetree- Philadelphia Research Center
mi
from
Philadelphia, PA
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 1/5/2016
CRI Lifetree- Philadelphia Research Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
An Open-Label and Double-Blind Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  1/7/2016
Clinical Research Facility
mi
from
Durham, NC
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
An Open-Label and Double-Blind Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 1/7/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Status: Enrolling
Updated:  1/7/2016
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Status: Enrolling
Updated: 1/7/2016
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Psychosis: Early Detection, Intervention and Prevention
Psychosis: Early Detection, Intervention and Prevention
Status: Enrolling
Updated:  1/7/2016
Maine Medical Center
mi
from
Portland, ME
Psychosis: Early Detection, Intervention and Prevention
Psychosis: Early Detection, Intervention and Prevention
Status: Enrolling
Updated: 1/7/2016
Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated:  1/12/2016
Massachusetts Correctional Institution - Framingham
mi
from
Framingham, MA
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated: 1/12/2016
Massachusetts Correctional Institution - Framingham
mi
from
Framingham, MA
Click here to add this to my saved trials
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated:  1/12/2016
South Middlesex Correctional Center
mi
from
Framingham, MA
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated: 1/12/2016
South Middlesex Correctional Center
mi
from
Framingham, MA
Click here to add this to my saved trials
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated:  1/12/2016
Massachusetts Correctional Institution - Norfolk
mi
from
Norfolk, MA
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated: 1/12/2016
Massachusetts Correctional Institution - Norfolk
mi
from
Norfolk, MA
Click here to add this to my saved trials
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated:  1/12/2016
Adult Correctional Institution - Men's & Women's Medium & Minimum Security Facilities
mi
from
Cranston, RI
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated: 1/12/2016
Adult Correctional Institution - Men's & Women's Medium & Minimum Security Facilities
mi
from
Cranston, RI
Click here to add this to my saved trials
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated:  1/12/2016
Massachusetts Correctional Institute - Old Colony Correctional Center
mi
from
Bridgewater, MA
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Status: Enrolling
Updated: 1/12/2016
Massachusetts Correctional Institute - Old Colony Correctional Center
mi
from
Bridgewater, MA
Click here to add this to my saved trials
Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss
Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss
Status: Enrolling
Updated:  1/12/2016
Brown University
mi
from
Providence, RI
Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss
Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss
Status: Enrolling
Updated: 1/12/2016
Brown University
mi
from
Providence, RI
Click here to add this to my saved trials
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Status: Enrolling
Updated:  1/13/2016
Barnes Jewish Hospital
mi
from
St. Louis, MO
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Status: Enrolling
Updated: 1/13/2016
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
Protocol 331-13-004: An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC 34712) (2 mg/Day Tablets) as an Adjunctive Treatment
Status: Enrolling
Updated:  1/14/2016
Emory University
mi
from
Atlanta, GA
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
Protocol 331-13-004: An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC 34712) (2 mg/Day Tablets) as an Adjunctive Treatment
Status: Enrolling
Updated: 1/14/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacotherapy in Depression With Panic Spectrum
Pharmacotherapy in Depression With Panic Spectrum
Status: Enrolling
Updated:  1/14/2016
Western Psychiatric Insititue and Clinic
mi
from
Pittsburgh, PA
Pharmacotherapy in Depression With Panic Spectrum
Pharmacotherapy in Depression With Panic Spectrum
Status: Enrolling
Updated: 1/14/2016
Western Psychiatric Insititue and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens
An Open-Label Eight-Week Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents: Mechanisms of Response
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens
An Open-Label Eight-Week Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents: Mechanisms of Response
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer
Status: Enrolling
Updated:  1/20/2016
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer
Status: Enrolling
Updated: 1/20/2016
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Harmonex Neuroscience Research
mi
from
Dothan, AL
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Harmonex Neuroscience Research
mi
from
Dothan, AL
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Dedicated Clinical Research
mi
from
Goodyear, AZ
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Dedicated Clinical Research
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
University of Arizona Clinical and Translational Science Center (CATS)
mi
from
Tucson, AZ
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
University of Arizona Clinical and Translational Science Center (CATS)
mi
from
Tucson, AZ
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
University of Arizona College of Medicine Dept of Psychiatry
mi
from
Tucson, AZ
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
University of Arizona College of Medicine Dept of Psychiatry
mi
from
Tucson, AZ
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
mi
from
Little Rock, AR
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
mi
from
Little Rock, AR
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
ATP Clinical Research, Incorporated
mi
from
Costa Mesa, CA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
ATP Clinical Research, Incorporated
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Synergy Clinical Research Center
mi
from
National City, CA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Synergy Clinical Research Center
mi
from
National City, CA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Neuropsychiatric Research Center for Orange County
mi
from
Orange, CA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Neuropsychiatric Research Center for Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Pacific Clinical Research Medical Group
mi
from
Orange, CA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Pacific Clinical Research Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Elite Clinical Trials, Incorporated
mi
from
Wildomar, CA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Elite Clinical Trials, Incorporated
mi
from
Wildomar, CA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Children's Hospital Colorado
mi
from
Aurora, CO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Amedica Research Institute, Incorporated
mi
from
Hialeah, FL
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Amedica Research Institute, Incorporated
mi
from
Hialeah, FL
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Kolin Research Group
mi
from
Winter Park, FL
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Kolin Research Group
mi
from
Winter Park, FL
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Institute for Behavioral Medicine
mi
from
Smyrna, GA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Psychiatric Associates
mi
from
Overland Park, KA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Precise Research Centers
mi
from
Flowood, MS
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Precise Research Centers
mi
from
Flowood, MS
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Biomedical Systems, Incorporated
mi
from
Saint Louis, MO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Biomedical Systems, Incorporated
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Center for Psychiatry and Behavioral Medicine, Incorporated
mi
from
Las Vegas, NV
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Center for Psychiatry and Behavioral Medicine, Incorporated
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
North Star Medical Research, LLC
mi
from
Middleburg Heights, OH
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
North Star Medical Research, LLC
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
IPS Research Company
mi
from
Oklahoma City, OK
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Summit Research Network (Oregon), Incorporated
mi
from
Portland, OR
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Summit Research Network (Oregon), Incorporated
mi
from
Portland, OR
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Focus and Balance, LLC
mi
from
San Antonio, TX
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Focus and Balance, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Grayline Clinical Drug Trials
mi
from
Witchita Falls, TX
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Grayline Clinical Drug Trials
mi
from
Witchita Falls, TX
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials